Evidence map›Paper›PMID 35935824›Full record

ArticleFrontiers in pharmacology2022

The Hypoglycemic Effect of JinQi Jiangtang Tablets Is Partially Dependent on the Palmatine-Induced Activation of the Fibroblast Growth Factor Receptor 1 Signaling Pathway.

Siming Li, Xiaoling Li, HeMeng Wang, Xinhang Jia, Haoyang Mao, Fangxin Dong, Tingting Zhao, Yuan Gao, Chen Zhang, Ruisong Bai and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Siming LiSchool of Pharmacy, Harbin University of Commerce, Harbin, China.
Xiaoling LiSchool of Pharmacy, Harbin University of Commerce, Harbin, China.
HeMeng WangCollege of Life Sciences, Tarim University, Alar, China.
Xinhang JiaSchool of Pharmacy, Harbin University of Commerce, Harbin, China.
Haoyang MaoSchool of Pharmacy, Harbin University of Commerce, Harbin, China.
Fangxin DongSchool of Pharmacy, Harbin University of Commerce, Harbin, China.
Tingting ZhaoAier School of Ophthalmology, Central South University, Changsha, China.
Yuan GaoSchool of Pharmacy, Harbin University of Commerce, Harbin, China.
Chen ZhangSchool of Pharmacy, Harbin University of Commerce, Harbin, China.
Ruisong BaiCollege of Life Sciences, Northeast Agricultural University, Harbin, China.
Ruihao LiuCollege of Life Sciences, Northeast Agricultural University, Harbin, China.
Lijun YanSchool of Pharmacy, Harbin University of Commerce, Harbin, China.
Yubin JiSchool of Pharmacy, Harbin University of Commerce, Harbin, China.
Na ZhangCollege of Food Engineering, Harbin University of Commerce, Harbin, China.
Wenfei WangCollege of Life Sciences, Northeast Agricultural University, Harbin, China.
Harbin University of Commerce · CNNortheast Agricultural University · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

JinQi Jiangtang tablet (JQJTT) is a Chinese patent medicine that has been shown to be beneficial for patients with diabetes both preclinically and clinically; however, the molecular mechanism underlying the effects of JQJTT remains unclear. In this study, surface plasmon resonance fishing was employed to identify JQJTT constituent molecules that can specifically bind to fibroblast growth factor receptor 1 (FGFR1), leading to the retrieval of palmatine (PAL), a key active ingredient of JQJTT.

Indexed as

fibroblast growth factor receptor (FGFR1)hypoglycemic effectJinQi Jiangtang tablets (JQJTT)palmatine (PAL)SPR fishing

Identifiers

PMID35935824
PMCPMC9354937
OpenAlexW4286562006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.